Open AccessGenerating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study
Author(s) -
Cathelijne H. van der Wouden,
Stefan Böhringer,
Erika Cecchin,
Ka Chun Cheung,
Cristina Lucía Dávila-Fajardo,
Vera H.M. Deneer,
Vita Dolžan,
Magnus IngelmanSundberg,
Siv Jönsson,
Mats O. Karlsson,
Marjolein Kriek,
Christina Mitropoulou,
George P. Patrinos,
Munir Pirmohamed,
Emmanuelle RialSebbag,
Matthias Samwald,
Matthias Schwab,
Daniela Steinberger,
Julia Stingl,
Gere SunderPlassmann,
Giuseppe Toffoli,
Richard M. Turner,
Mandy H van Rhenen,
Erik W. van Zwet,
Jesse J. Swen,
H. J. Guchelaar
Publication year - 2020
Publication title -
pharmacogenetics and genomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.579
H-Index - 140
eISSN - 1744-6880
pISSN - 1744-6872
DOI - 10.1097/fpc.0000000000000405
Subject(s) - pharmacogenomics , operationalization , precision medicine , pharmacogenetics , personalized medicine , medicine , clinical endpoint , clinical study design , clinical trial , intensive care medicine , bioinformatics , pharmacology , biology , genetics , philosophy , epistemology , pathology , genotype , gene
Pharmacogenetic panel-based testing represents a new model for precision medicine. A sufficiently powered prospective study assessing the (cost-)effectiveness of a panel-based pharmacogenomics approach to guide pharmacotherapy is lacking. Therefore, the Ubiquitous Pharmacogenomics Consortium initiated the PREemptive Pharmacogenomic testing for prevention of Adverse drug Reactions (PREPARE) study. Here, we provide an overview of considerations made to mitigate multiple methodological challenges that emerged during the design.